Experienced in Menopause

Khalil Zaman

Rue De Bugnon 46, 
Lausanne, VD, CH 
Experienced in Menopause
Rue De Bugnon 46, 
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Khalil Zaman practices in Lausanne, Switzerland. Mr. Zaman is rated as an Experienced expert by MediFind in the treatment of Menopause. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Agranulocytosis, and Mastectomy.

His clinical research consists of co-authoring 124 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Menopause.

Gender
Male

Locations

Rue De Bugnon 46, Lausanne, VD 1003, Switzerland
Other Locations
Basel, BS, Switzerland
Bern, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Phase: Phase 2
Online Mindfulness-Based Cancer Recovery (MBCR) Program for Patients Living With a Gynecological Cancer: a Pilot Randomized Controlled Study.
Online Mindfulness-Based Cancer Recovery (MBCR) Program for Patients Living With a Gynecological Cancer: a Pilot Randomized Controlled Study.
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Drug
Study Drug: Eribulin Mesilate
Study Phase: Phase 2
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Drug
Study Drug: anti-EGFR-IL-dox
Study Phase: Phase 2
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Enrollment Status: Terminated
Publish Date: June 16, 2021
Intervention Type: Other, Drug
Study Drug: Ribociclib
Study Phase: Phase 3
View 7 Less Clinical Trials

124 Total Publications

Retrospective comprehensive analysis of regional lymph node recurrence in breast cancer patients (REASON study).
Retrospective comprehensive analysis of regional lymph node recurrence in breast cancer patients (REASON study).
Journal: Journal of cancer research and clinical oncology
Published: April 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Zaman's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile